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with newly diagnosed depressive disorder. The patients were followed up for one 
year after the index date (the first date of diagnosis). Psychotropic drugs used to 
treat depressive disorder included first- and/or second-generation antidepressant, 
benzodiazepine, sulpiride, and antipsychotics. The treatment duration and time to 
treatment by gender and age were evaluated by Cox regression model. Results: 
A total of 5,464 patients (men: 3,483, mean age: 36.1±9.9) with depressive disorder 
was identified. Median treatment duration was 123 days (men: 150 days, women 
92 days). 90.1% of patients was prescribed at least one psychotropic drug within 
30 days from the first date of diagnosis (84.5% in women and 93.1% in men). The 
proportion of patients who were prescribed at least one psychotropic drug for the 
first time after 6 months from the index date was 5.6% (men: 3.8%, women: 9.1%). 
The result showed that older patients were more likely to be treated longer period. 
In addition, men tend to be prescribed at least one psychotropic drug in a shorter 
period of time from the index date compared to that in women. ConClusions: 
This study suggested the trend of treatment disparity between men and women as 
well as age in working population with regard to treatment duration and time to 
prescription. Further study is needed for generalizability.
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objeCtives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe (France, Germany, Spain, Sweden and UK). 
Objectives are to describe the functioning of patients with major depressive disorder 
(MDD) and factors associated with functional impairment. Here we compare charac-
teristics and outcomes of patients switching antidepressant treatment (ADT) with 
those initiating ADT at baseline, on an interim 1000-patient dataset. Methods: 
Outpatients were recruited from primary or secondary care. Inclusion criteria were: 
DSM-IV-TR diagnosis of MDD, age 18-65 years, initiation or first switch to an ADT, in 
monotherapy. In addition to socio-demographics and disease history, data collec-
tion included clinician assessments (MADRS and CGI-S) and patient-rated scales 
evaluating depression (PHQ-9), functioning (SDS), work productivity (WPAI-SHP) 
and quality of life (QoL - EQ-5D). Results: Of 947 analysable patients at inclusion, 
213 (23%) patients were switching (76% for lack of efficacy), versus 716 (77%) initi-
ating ADT. Switchers were slightly older (mean age 46 versus 43 years) and more 
often female (77% vs. 72% women). Switching patients had more severe symptom 
profiles: more had previous depressive episodes (34% vs. 24%) and previous suicide 
attempts (16% vs. 12%). Severity of current episode was greater for switchers (46% 
vs. 36% with a CGI-S score above “markedly ill”; 48% versus 38% with a PHQ-9 score 
above the severe depression threshold). MADRS scores were similar: 18.1 versus 
17.6. QoL was poorer for switchers (EQ-5D: 0.449 vs. 0.567), as was overall patient 
functioning (47% vs. 36% with an SDS total score in the highest quartile), while no 
difference was found for absenteeism (35% vs. 34%) and presenteeism (49% vs. 50%) 
(WPAI-SHP). ConClusions: Patients switching ADT had more severe symptom 
profiles, lower quality of life and higher functional impairment, compared to non-
switching patients.
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objeCtives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe to describe the functioning of patients 
with major depressive disorder (MDD) and factors associated with functional 
impairment. Here we report the impact of patient-reported cognitive dysfunc-
tion (PRCD) on quality of life (QoL), work and overall functioning at baseline, on 
a preliminary 1000-patient dataset. Methods: Outpatients were recruited from 
primary or secondary care. Inclusion criteria were: DSM-IV-TR diagnosis of MDD, 
18-65 years old, initiation or first switch to an antidepressant, in monotherapy. 
Functioning was assessed by the SDS (Sheehan Disability Scale), work productiv-
ity by the WPAI-SHP (Work Productivity and Activity Impairment Questionnaire) 
and QoL by the EQ-5D (EuroQol-5 Dimensions) and SF-12 (12-Item Short-Form 
Health Survey). PRCD was assessed by the Perceived Deficit Questionnaire 5-item 
(PDQ-5). Descriptive analyses stratified on PDQ-5 quartiles were complemented 
with ANCOVA adjusted for severity of depression. Results: At inclusion, over 947 
analysable patients, mean PDQ-5 score (ranging from 0 to 20) was 11.5 (SD= 4.4). 
PRCD was associated with impairment of overall functioning, QoL and productiv-
ity. SDS total scores were 14.4, 18.5, 20.2, and 23.6 (first to fourth PDQ-5 quartiles, 
respectively) (p< 0.001). Similar patterns were observed for WPAI-SHP presentee-
ism scores (impairment while working: from 36.9% in first quartile to 64.4% in 
fourth quartile, p< 0.001; overall work impairment: from 41.5% to 71.3%, p< 0.001). 
These associations remained statistically significant after adjustment for baseline 
depression severity in multivariate analyses. A negative impact of PRCD was also 
observed on sick-leave length and on QoL. ConClusions: At inclusion, subjective 
cognitive dysfunction in depressed patients was associated with poorer function-
ing, work productivity and QoL. This is in addition to any negative impact of the 
to others antipsychotics in terms of PANSS total score and CGI-S score and a similar 
effect as compared to placebo on all metabolic outcomes. The probability to have 
a lower impact than aripiprazole on weight increase and fasting glucose level was 
respectively 75.5% and 65.9%. Probabilities to have a lower impact on cholesterol 
level and triglycerides compared to olanzapine, quetiapine or riperidone varied 
from 98% to 100%. ConClusions: Efficacy has been demonstrated for all reviewed 
treatments vs. placebo, with a similar effect. Lurasidone had a similar effect as 
compared to placebo and a less negative impact than olanzapine, quetiapine and 
risperidone on weight increase, triglycerides, total cholesterol level and than olan-
zapine on fasting glucose level.
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objeCtives: Vortioxetine (Lu AA21004) is an investigative multimodal antide-
pressant which demonstrated efficacy, safety and tolerability in Major Depressive 
Episode (MDE). The comparison of vortioxetine to marketed antidepressants guides 
decison makers and clinicians in their choice of treatment. The main study objective 
was to generate comparative evidence for the efficacy and acceptability of vortiox-
etine in MDE. Methods: Indirect comparisons were performed by meta-regression 
analysis, an extension of classical random-effect meta-analyses, to compare vorti-
oxetine to agomelatine, escitalopram, duloxetine, sertraline, venlafaxine IR/XR and 
vilazodone. To ensure comparability between studies, in terms of selection of patient 
population and exposure to treatment, only investigational drug and placebo arms 
from pre-registration placebo-controlled studies were included in the base case 
analyses. The main outcomes were efficacy, measured as the standardized mean dif-
ference between active treatment and placebo control in the change from baseline 
to 2 months of the primary endpoint (MADRS or HAM-D total score), and accept-
ability (the withdrawal rate due to adverse events) and expressed as the logarithm of 
the odds ratio (OR) between active treatment and placebo. Sensitivity analyses were 
performed with the inclusion of post-marketing authorization studies, adjustment 
for age/gender and on response and remission. Results: For efficacy, treatment 
effect estimates and p-values for vortioxetine versus comparators were: -0.16(0.11) 
versus agomelatine (negative effect favours vortioxetine); 0.09(0.42) versus dulox-
etine; -0.05(0.70) versus escitalopram; -0.04(0.83) versus sertraline; 0.12(0.33) versus 
venlafaxine IR/XR and -0.24(0.11) versus vilazodone. For acceptability, all but one OR 
(< 1) favoured vortioxetine: 1.77(0.03) versus agomelatine; 0.75(0.26) versus dulox-
etine; 0.67(0.28) versus escitalopram; 0.30(0.01) versus sertraline; 0.47(0.01) versus 
venlafaxine and 0.64(0.18) versus vilazodone. Meta-regression adjusted for age and 
gender demonstrated the robustness of the estimated differences between treat-
ments, as did sensitivity analyses including post-marketing trials. ConClusions: 
Vortioxetine is a promising intervention with efficacy comparable to marketed anti-
depressants in MDE and a favourable acceptability profile.
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objeCtives: The therapy of Attention Deficit/Hyperactivity Disorder (ADHD) with 
methylphenidate or atomoxetine, formerly only related to children and adolescents, 
is now extended to the adult population. Little is known about treatment patterns 
in Austria. The aim of this study was to evaluate the medication patterns of ADHD 
in 2012 in Austria, stratified by age and sex. Methods: The data analysis refers to 
the accounting data of the 13 major Austrian health insurance funds, covering more 
than 97% of the Austrian population. Provided in a pseudonymised manner, with 
availability of the individual patient parameters age and sex, all dispensed medica-
tion of methylphenidate or atomoxetine is included in the descriptive analysis. The 
prevalence of ADHD medication is evaluated regarding age and sex. Furthermore the 
prescribed daily dose in relation to the defined daily dose is pointed out. Results: 
A total of 9120 patients with ADHD medication in 2012 are included in the analy-
sis (22% female). One per cent of all patients with ADHD medication is in the age 
cohort of under 6 years, 47% are between 6 and 13, 22% are between 14 and 17, and 
30% are adults (18+). The relation between the defined daily dose (ddd) to the pre-
scribed daily dose (pdd) shows that 86% of children and adolescents have less than 
366 pdd in the whole year and only 1% has more than 732 pdd. 81% of the adults 
have less than 366 pdd and 6% have more than 732 pdd. ConClusions: While the 
variety of prescribed daily dose per patient is homogeneous during childhood and 
adolescence, this parameter spreads widely in adults. This could be an indicator of 
overuse or misuse. As the results reflect the prescription reality they can be used 
as a solid basis for further discussions, future evaluations and interventions about 
ADHD medication in Austria.
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objeCtives: Treatment disparity by gender and age among patients with depres-
sive disorder in working population has not been examined in Japan. This study 
examined treatment disparity by gender and age among patients newly diagnosed 
with depressive disorder based on the claims database of health insurance socie-
ties between 2008 and 2011 in Japan. Methods: Retrospective cohort database 
(N= 600,000) was followed up for four years to identify patients (18 ≤ age ≤ 65) 
